
    
      The duration of study per patient will be up to 108 weeks, including a screening period of up
      to 4 weeks, a treatment period of 12 weeks and a post-treatment safety follow-up period of up
      to 92 weeks.

      Patients completing the 12-week treatment period may enter an optional long-term extension
      study in which all subjects will receive vatelizumab.
    
  